The global cervical cancer diagnostic market was valued at USD 7 billion in 2015 and is projected to grow at a CAGR of 5.9% over the forecast period. Women between the age group of 20 and 60 years are usually more prone to this ailment, which is expected to increase the screening and diagnostics procedures of cervical cancer.
Cervical cancer is amongst one of the most common causes of deaths in U.S. women. The U.S. has a very high prevalence of cervical cancer, which is a key driving force for growth of the market. According to the American Cancer Society, an estimated 12,990 new cases of invasive cervical cancer would be diagnosed and would cause the death of 4,120 women in 2016. The death rate due to cervical cancer has dropped over the last 40 years by up to more than 50%, thus indicating the growing adoption of screening procedures, such as Pap test and HPV testing. In the U.S., Hispanic women are at a higher risk of developing cervical cancer followed by African-Americans, Pacific-Islanders, and white women. Alaskans and American Indians are expected to be at the lowest risk of developing it.
The presence of favorable policies related to reimbursement is another key factor anticipated to boost the number of screening tests over the forecast period. Additionally, technology is a key enabler of the improving access and affordability of various diagnostic tests across the U.S. The technological advancements in terms of new diagnostic equipment, diagnostic procedures, and screening techniques are expected to have a positive impact on the market as well. Some of the key biomarkers available are long noncoding RNAs (lncRNA), mRNA, m6A, etc. The increasing demand for novel treatment and biomarkers in order to improve screening results is one of the pivotal factors driving the market.
Pap test held a majority share of 49.6% of the segment in 2015. Pap test helps diagnose abnormal cells of the cervix that may potentially develop into cancer at a later stage. This test accounts for the largest share on account of the high efficiency of this test. Furthermore, the increasing awareness regarding early diagnosis contributes to the growth of this segment.
HPV testing is expected to grow at a lucrative CAGR of 15.3% due to the upsurge in the demand for technologically advanced diagnostics procedures at low costs and further developments in the use of various biomarkers along with the regular screening procedures. Hence, the enhanced accuracy and sensitivity of the screening tests is one of the crucial factors anticipated to propel growth in the coming years.
In 2015, North America accounted for the maximum revenue share of 48.3% and is closely followed by Europe. The U.S. is the most important sector and captured the majority share of the North American segment. The growing prevalence of cervical cancer in the region and increasing awareness regarding early diagnosis can be attributed to the large share of the region.
Asia Pacific is expected to emerge as the fastest-growing region with a CAGR of 9.6% over the forecast period. Favourable government initiatives and increasing diagnostic rates are expected to drive the growth of the market in the region.
Key players of this market include Abbott Laboratories; Cooper Surgical, Inc.; Becton, Dickinson and Company (BD); Hologic, Inc.; Quest Diagnostics; QIAGEN; Guided Therapeutics; Siemens; OncoHealth Corp.; Arbor Vita; Zilico Ltd.; and Beckman Coulter, Inc. The companies are currently focusing on the technological advancements in diagnostic techniques, such as liquid-based cytology. In 2014, F. Hoffmann-La Roche Ltd. developed a fully automated CINtec PLUS* cytology test to remove unhealthy tissue from the cervical site before the development of cancerous tissue. Moreover, Roche also announced that the company had received a U.S.FDA approval for Avastin, a biologic medicine plus chemotherapy for treating advanced cervical cancer patients.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.